Increase in prevalence of bacterial infection across the globe as become an opportunity for many. It generates lucrative option for revenue generation for the stake holders in — carbapenem-based antibiotics market. These antibiotics are used to treat diseases like pneumonia which exists because of varied reasons. It can be developed due to multiple reasons like prolonged hospital stay and side effects of medical conditions like organ transplant and Cancer. It has the potential to deter the efficacy of any ongoing treatment and is fatal at times. Pneumonia is considered to be difficult to treat and carbapenem-based antibiotics have found to be effective in treatment.
Open surgeries induce bacterial infections
Center for disease control states that patients who have been admitted in hospital because of various reasons like treatment of immunosuppressive disease and side effects of improper infection control treatment have the tendency to develop pneumonia which is hospital-acquired. Apart from this pneumonia, different types of diseases induced by bacteria have high prevalence which propel the global market for carbapenem-based antibiotics.
Request Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=4425
Open surgeries are required during the treatment of many chronic health conditions. Carbapenem-based antibiotics are administered as a preventive measure ahead of such surgeries to prevent any changes of bacterial infections post-surgery. World Health organization stresses on protocols for controlling infections. World Health Organization indicates that 30% of the total diseases acquired across the globe are induced as post-surgery impact. This data also significantly surges the demand for carbapenem-based antibiotics.
Patent expiry is a challenge
Patent expiry is a challenge before global market. Ertapenem is considered to be most extensively used antibiotic which is based on carbapenem but its patent expired in the end of the year 2017. Different players on regional as well as global level acknowledged the gap created in the market by expiry of this product. They are busy launching medicines that are the generic forms of Ertapenem. Aurobindo Pharma is one of the major stake holders that launched its generic version named Invanz injection which also received acceptance for FDA. It is an antibiotic which is based on carbapenem. It sis jointly created by Dohme Corp. and Merck Sharp and is used in treatment of a wide range of bacterial infections. Carbapenem-based antibiotics’ generic versions have been launched in regions like Europe and North America which generates great amount of revenue in global market. Low prices of generic products works in favor of stake holders. Low prices promotes their adoption as they are affordable by larger population segment. Manufacturers have recognized this trend and are currently striving to strengthen their market presence in generic medicines which is extensively used by low and medium income groups. Regions like North America, Europe and East Asia are witnessing surge in supply chain operators which results in greater revenue generation in global market.
Request Research Methodology- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4425
Prominent players in global market for carbapenem-based antibiotics are Pfizer Inc., Sumitomo Dainippon Pharma Co., Ltd. and Merck Co. These players cumulatively generate 92% of the total market revenue of the global market.
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports. Check other healthcare industry reports here.
Name: James Hilton
Email: Send Email
Release ID: 88941466